John Rondoni - 15 May 2026 Form 4 Insider Report for Inspire Medical Systems, Inc. (INSP)

Reporting relationship: Title: Chief Product and Innovation Officer.
Issuer ticker: INSP
Reported as of: 15 May 2026
Net transaction value: -$114,302
SEC form: 4
Accepted by SEC: 19 May 2026, 16:05:13 UTC
Prior SEC filing: 15 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Bryan Phillips, Attorney-in-Fact for John Rondoni

Key filing fact

John Rondoni filed Form 4 for Inspire Medical Systems, Inc. (INSP) on 19 May 2026.

Key facts

This page summarizes John Rondoni's Form 4 filing for Inspire Medical Systems, Inc. (INSP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 May 2026, 16:05.

Change

Previous filing in this sequence was filed on 15 May 2026.
Current net transaction value: -$114,302.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001932219 Primary reporting owner

Rondoni John

Relationship: Title: Chief Product and Innovation Officer.
Address: C/O INSPIRE MEDICAL SYSTEMS, INC., 5500 WAYZATA BLVD., SUITE 1600, GOLDEN VALLEY
Signature: /s/ Bryan Phillips, Attorney-in-Fact for John Rondoni
Signature date: 19 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INSP transaction

Common Stock

Sale

Transaction value: $114,302
Shares: -2,641
Change %: -8.9%
Price: $43.28
Shares after: 27,165
Date: 15 May 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.09 to $43.40. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC remarks

Title: Chief Product and Innovation Officer.